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Abstract
Background: Fish fillet consumption is associated with beneficial health effects; however, little is known about 
whether consuming other parts of the fish such as head, backbone, skin, cut-offs, and entrails (collectively 
known as residuals) will provide comparable effects.
Objective: The aim of the study was to investigate if  daily supplementation with cod residual protein powder 
would impact lipid metabolism in healthy adults.
Methods: Forty healthy, lean, physically active participants (18 women, 22 men) with normal body mass index 
consumed 8.1 g of proteins daily from cod residual protein powder (Cod-RP) or placebo (control) for 8 weeks.
Results: Cod residual protein powder supplementation lowered fasting serum nonesterified fatty acids and in-
creased serum total bile acid concentrations significantly when compared with control supplementation. Fast-
ing serum low-density lipoprotein cholesterol and apolipoprotein (Apo) B concentrations, as well as the total 
cholesterol:high-density lipoprotein (HDL) cholesterol and ApoB:ApoA1 ratios, were significantly  decreased 
within the Cod-RP group, but these changes were not different from the control group. Fasting serum con-
centrations of triacylglycerol, total cholesterol, HDL cholesterol, and ApoA1 were not changed within or 
between groups.
Conclusion: Eight weeks of daily supplementation with 8.1 g Cod-RP seems to be sufficient to affect lipid 
metabolism in healthy, lean, physically active adults.
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The burden of cardiovascular disease (CVD) is one of our largest health challenges globally (1). Certain dietary patterns, such as a high intake of 
fish, are associated with reduced risk of developing distur-
bances in lipid metabolism, which in turn reduces the risk 
of CVD (2–4). High physical activity level is also associ-
ated with a lower risk of CVD development through ben-
eficial effects on lipid metabolism (5, 6). Fish and seafood 
are sources of long-chain n-3 polyunsaturated fatty acids 
(PUFAs), which have been emphasized when explaining 
Popular scientific summary
• Fish fillet consumption is associated with beneficial health effects, however, little is known if  consum-
ing the fish residuals (head, backbone, skin, cut-offs and entrails) will provide comparable effects.
• We investigated if  daily supplementation with cod residual protein powder would impact lipid 
 metabolism in healthy, lean, physically active adults.
• Cod residual protein supplementation (8.1 g/day) for eight weeks reduced fasting nonesterified fatty 
acid and increased total bile acid serum concentrations when compared with Control  (placebo) 
supplementation.
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their cardioprotective effects, whereas the possible contri-
butions of other marine nutrients such as proteins have 
often been overlooked. Recently, several clinical studies 
have demonstrated that intake of lean fish such as cod, 
which has a low long-chain n-3 PUFA content but a high 
protein content, is associated with beneficial effects on 
circulating metabolites related to lipid metabolism. These 
effects include higher circulating high-density lipoprotein 
(HDL) cholesterol (7, 8), lower low-density lipoprotein 
(LDL) cholesterol (9), and lower triacylglycerol (TAG) 
concentrations (7, 8, 10, 11). Further, cod fillet intake 
has showed a tendency to reduce nonesterified fatty acid 
(NEFA) concentrations in normal-weight adults (12). 
Cholesterol and NEFA lowering effects have also been 
demonstrated in obese rats that were fed diets containing 
proteins from cod fillet (13–16).
Both the cod fillet and residuals from cod fillet produc-
tion (head, backbone, skin, cut-offs, and entrails) contain 
high quality proteins (17). Supplementation with cod 
residual protein powder reduced serum NEFA concen-
tration in overweight and obese adults (18) and protein hy-
drolysates from residuals of other fish species have shown 
cholesterol lowering effects in rats (19, 20). However, cod 
supplement intervention studies in lean and/or physically 
active adults are, to our knowledge, lacking from the liter-
ature. New technologies have allowed cod residuals to be 
processed efficiently onboard the fishing vessels, resulting 
in high quality fishmeal powder with high protein content 
of 60–70% of the dry weight (21). Cod residual fishmeal 
is currently utilized for fish and animal feeds and should 
be further exploited for human consumption as a safe and 
high-quality protein source, which could generate add-
ed-value products for the industry.
The aim of the present study was to investigate the im-
pact of daily supplementation with cod residual protein 
powder (Cod-RP) on lipid metabolism in lean, physically 
active adults. Our hypothesis was that 8 weeks of daily 
supplementation with 8.1 g protein from Cod-RP would 
beneficially affect serum concentrations of lipids and 
NEFA in lean, physically active adults when compared to 
a similar group receiving control capsules.
Materials and methods
Participants
The current study cohort consisted of lean, physically 
active adults. Participants were recruited through local 
newspapers, the intranet at Haukeland University Hospi-
tal (Bergen, Norway), the project’s website, social media, 
and posters in and around Bergen. Recruitment for the 
study took place between December 2015 and March 
2016, and the intervention was conducted between Feb-
ruary and June 2016. All participants provided written 
informed consent before they were enrolled in the study.
The eligibility criteria were as follows: age between 20 
and 55 years, fasting blood glucose <7.0 mmol/L, body 
mass index (BMI) ≥ 18.5 kg/m2, and a stable exercise pro-
gram including two or more training sessions per week. 
Eligibility criteria also included a stable body weight with 
less than 5 kg fluctuation in the last 3 months and body fat 
percentage between 12 and 35% for women and between 
5 and 25% for men. Exclusion criteria were as follows: 
known diseases affecting insulin secretion, heart, intes-
tinal, or kidney function; use of prescribed medications 
for high cholesterol; allergies towards seafood, milk, or 
gluten; and tobacco use exceeding 10 cigarettes or snus/
day. Candidates taking dietary supplements, consuming 
>200 g/week of fish and seafood, and pregnant or lactat-
ing women were not included in the study.
Design, intervention, and study protocol
This randomized, double-blind intervention study with 
a  parallel design was conducted at the University of 
 Bergen (Bergen, Norway). Fifty participants were in-
cluded in the study and stratified according to gender 
and age by the project manager. The participants con-
sumed capsules containing Cod-RP from Northeast At-
lantic cod (Gadus morhua) or placebo capsules (control). 
Participants in the Cod-RP group consumed 27 capsules 
daily (three doses), providing 8.1 g of  cod protein, and 
participants in the control group consumed 27 capsules 
per day (three doses) devoid of  cod protein. To ensure 
double-blinding, the capsules were coded by the manu-
facturer. We assessed compliance by interviewing partic-
ipants at 4 weeks after study start and at the end point 
visit. Participants were encouraged to report any devia-
tions from the study protocol.
Before the study, candidates were screened for eligibil-
ity by measuring fasting blood glucose concentration with 
a Contour blood glucose meter (Bayer Consumer Care 
AG, Basel, Switzerland), height by using a stadiometer 
(Telescopic Measuring Rod MZ10023-3, ADE, Hamburg, 
Germany), and body composition by using a bioelectrical 
impedance analyzer (InBody 720, Seoul, Korea). During 
the study period, participants were instructed not to make 
changes in their habitual diet or level of physical activ-
ity. The participants attended two study visits, at baseline 
and after 8 weeks. Both study visits were conducted in the 
morning between 7 and 11 AM after an overnight fast 
(>10 h), with no intake of food or drink except water, and 
no use of medications or tobacco. Participants were also 
instructed to avoid intensive physical activity and alco-
hol 24 h before study visits. Body composition was mea-
sured at baseline and end point. Fasting blood samples 
were collected at baseline and end point using Vacutainer 
SST II Advanced Plus (Becton, Dickinson and Company, 
 Franklin Lakes, NJ, USA) for serum isolation. Serum 
samples were stored at –80°C until analysis.
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Analysis of estimated dietary intake
Participants recorded their diet for 5 consecutive days, in-
cluding at least 1 weekend day, prior to the baseline and 
end point visits. Dietary food records were provided to 
the participants, and they were instructed to give detailed 
information about the food and drink they consumed, 
including descriptions of weight or volume. The partici-
pants’ intake of energy and macronutrients were estimated 
using the dietary assessment software Dietist XP version 
3.2 (Kost och Näringsdata, Stockholm AB, Sweden). Pro-
tein content from the intervention capsules was included 
in the estimation of protein intake in the Cod-RP group 
at the end point registration.
Production and analysis of intervention capsules
The cod used in the present study were caught and pro-
cessed onboard the factory trawler Granit (Halstensen 
Granit AS, Bekkjarvik, Norway). Cod residuals from 
the cod fillet production were ground, heat treated, and 
pressed to separate the aqueous fraction (stickwater) from 
the solid phase (press cake). The solid phase was dried to a 
press cake meal onboard the trawler, while the stickwater 
was frozen, transported to land, thawed, and concentrated 
before it was mixed with the press cake meal and dried to a 
protein powder (Seagarden AS, Karmøy, Norway).
The capsules were produced by Pharmatech AS 
(Fredrikstad, Norway). The Cod-RP capsules contained 
474.3 mg of Cod-RP, 5.3 mg of magnesium stearate, and 
5.3 mg silica per capsule, and the control capsules con-
tained 4.6 mg of each of the two processing aids per cap-
sule. Microcrystalline cellulose was used as stabilizer in 
the Cod-RP capsules (42.2 mg/capsule) and as replace-
ment for cod residual powder in the control capsules 
(454.0 mg/capsule). Analyses of amino acids, taurine, and 
fatty acids in the intervention capsules were conducted by 
Nofima BioLab (Bergen, Norway).
Analyses of serum
Concentrations of total bile acids (TBA) and NEFA in 
serum were analyzed on the Cobas c 111 system (Roche Di-
agnostics GmbH, Marburg, Germany) using the  Diazyme 
TBA Assay (BioPacific Diagnostic Corporation, Bellevue, 
WA, USA) and the NEFA FS kit (Diagnostics Systems, 
Holzheim, Germany), respectively. Total cholesterol, LDL 
cholesterol, HDL cholesterol, and TAG concentrations in 
serum were analyzed on the Cobas c 111 system using the 
appropriate kits from Roche Diagnostics. Apolipoprotein 
(Apo) A1 and ApoB were analyzed by routine methods at 
the Laboratory of Clinical Biochemistry at the Haukeland 
University Hospital (Bergen, Norway).
Outcome and sample size calculation
The outcome of this study was changes in serum markers 
of lipid metabolism in healthy, lean adults after 8 weeks 
of supplementation with Cod-RP. A sample size calcula-
tion based on power analysis for the study was not feasi-
ble because, to the best of our knowledge, the effects of 
supplementation with Cod-RP on lipid metabolism have 
not before been investigated in lean, physically active 
adults. Two studies with resemblance to the current study 
have investigated the effects of 8 weeks of protein supple-
ments from cod fillet (9) or cod residuals (18) on glucose 
regulation, NEFA concentration, and/or lipid metabolism 
in adults with overweight or obesity. In these studies, be-
tween 12 and 18 participants in each group were enough 
to discover measurable effects. However, the studies used 
a lower dose (3 or 6 g/day) of cod protein and an obese/
overweight population, whereas the current study used a 
higher dose of 8.1 g/day of cod protein and a lean pop-
ulation with high physical activity. The current study is 
therefore considered a pilot that contributes to building 
knowledge in a new field of nutrition research and in gen-
erating new hypotheses. The target for the current study 
was to recruit 50 participants (25 in each group).
Statistical analyses
The statistic program SPSS Statistics version 25 (IBM 
Corp. IBM SPSS for Windows, Armonk, NY, USA) was 
used to perform statistical analysis. The 40 participants 
who completed the study in accordance with the proto-
col were included in the statistical analysis. Variables were 
evaluated for normality by the Shapiro–Wilk test, Q-Q 
plots, and histograms. Most variables were within normal 
distribution. Variables that were not normally distributed 
were log-transformed before parametric statistical tests 
were performed. Baseline-to-end point changes within 
groups were tested using the paired-samples t-test. The 
independent samples t-test was used to compare changes 
between the Cod-RP group and the control group. A p-
value less than 0.05 was considered statistically significant.
Results
Participant characteristics
Fifty participants, 24 women and 26 men, were recruited 
and randomized to one of the two experimental groups, 
and of these, 40 participants completed the intervention 
period according to the study protocol. Four participants 
(8%) withdrew from the study (one from the Cod-RP group 
and three from the control group). Six participants (12%) 
were excluded from statistical analysis due to noncompli-
ance (n = 5) or acute disease (n = 1). Noncompliance was 
defined as not following study protocol, which included 
failing to take the intervention capsules, initiating use of 
mediations, or implementing dietary changes that could in-
criminate the study outcome. Participant flow during the 
study is presented in Fig. 1. Age, BMI, body weight, body 
fat percentage, body muscle percentage, and tobacco use 
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were similar between groups at baseline (Table 1). BMI, 
body weight, body fat percentage, and muscle mass percent-
age were not changed within or between the two interven-
tion groups from baseline to end point (data not presented).
Concentrations of total bile acids, nonesterified fatty acids, 
and lipids in serum
The serum NEFA concentration was significantly 
 reduced and the serum TBA concentration was sig-
nificantly increased in the Cod-RP group compared 
with  the control group after the 8 week intervention 
(Table 2).
Fasting serum LDL cholesterol and ApoB concen-
trations, as well as total cholesterol:HDL cholesterol 
and ApoB:ApoA1 ratios, were significantly decreased 
within the Cod-RP group, but these changes were not 
significantly different from the control group. Serum con-
centrations of TAG, total cholesterol, HDL  cholesterol, 
and ApoA1 were not significantly changed within or be-
tween the groups after 8 weeks of supplementation.
Estimated macronutrient intake
The participants’ dietary intake was reported prior to 
the baseline and end point visits. Estimated intake of 
 energy, fat, and carbohydrate were not changed within 
or  between the groups after 8 weeks of  intervention 
(Table 3). The increased estimated protein intake within 
the Cod-PR group from baseline to end point corre-
sponded with the protein content of  these capsules 
(8.1 g/day), but this change in protein intake was not sig-
nificantly different when compared to change within the 
control group.
Fig. 1. This flow diagram displays the progress of participants through the study. If  participants did not comply with the study 
protocol, they were excluded from statistical analyses. We defined noncompliance as not following the study protocol regarding 
dietary changes (including fish intake), changes in physical activity habits, and not taking the intervention capsules. Cod-RP, cod 
residual protein powder.
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Table 1. Participant characteristics at baseline
Cod residual protein powder (n = 19) Control (n = 21) p
Mean Standard deviation Mean Standard deviation
Women/men 7/12 11/10 0.36
Age (years) 28.0 6.9 30.5 7.2 0.28
Body weight (kg) 77.0 16.0 73.1 11.5 0.39
Body mass index (kg/m2) 24.8 2.8 23.8 2.3 0.25
Fat (%) 19.7 6.8 19.4 6.7 0.89
Muscle (%) 45.4 4.7 45.4 4.4 0.95
Tobacco user (n) 1 2 1.00
Note: Results are presented as mean and standard deviation. Groups were compared at baseline using Pearson’s chi-square test for categorical data and 
independent samples t-test for continuous data.
Table 2. Total bile acids, lipids, and nonesterified fatty acids in serum
Baseline 8 weeks p† p‡
Mean Standard deviation Mean Standard deviation
Total bile acids (mmol/L) 0.0081
 Cod residual protein powder (Cod-RP) group 2.68 1.46 3.91 2.21 0.0023
 Control group 2.92 1.92 2.72 1.38 0.83
Total cholesterol (mmol/L) 0.81
 Cod-RP group 4.82 0.85 4.73 0.86 0.24
 Control group 4.68 0.66 4.54 0.61 0.34
Low density lipoprotein (LDL) (mmol/L) 0.99
 Cod-RP group 2.90 0.77 2.74 0.74 0.0061
 Control group 2.66 0.57 2.52 0.61 0.18
High density lipoprotein (HDL) (mmol/L) 0.16
 Cod-RP group 1.68 0.48 1.73 0.54 0.33
 Control group 1.79 0.45 1.74 0.37 0.32
Total cholesterol:HDL 0.46
 Cod-RP group 3.08 0.99 2.94 0.91 0.039
 Control group 2.75 0.76 2.70 0.63 0.75
ApoA1 (g/L) 0.22
 Cod-RP group 1.54 0.27 1.57 0.31 0.25
 Control group 1.61 0.29 1.60 0.26 0.61
ApoB (g/L) 0.79
 Cod-RP group 0.79 0.17 0.76 0.16 0.041
 Control group 0.74 0.13 0.71 0.16 0.47
ApoB:ApoA1 0.56
 Cod-RP group 0.53 0.17 0.50 0.16 0.026
 Control group 0.47 0.15 0.46 0.14 0.44
Nonesterified fatty acids (mmol/L) 0.0032
 Cod-RP group 0.60 0.33 0.52 0.25 0.084
 Control group 0.46 0.20 0.61 0.26 0.012
Triacylglycerol (mmol/L) 0.24
 Cod-RP group 0.81 0.33 0.84 0.31 0.55
 Control group 0.78 0.25 0.74 0.34 0.20
Note: Results are presented as mean and standard deviation. Serum indicators of lipid regulation are presented for 19 participants in the Cod-RP group 
and 21 participants in the control group.†Within-group differences were compared using a paired-samples t-test.‡Between-group changes were com-
pared using the independent samples t-test. The level of significance was set to <0.05.
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Daily intake of amino acids, taurine, and fatty acids from capsules
The daily intakes of indispensable amino acids, the non-
essential amino acid glycine, the organic acid taurine, and 
the fatty acids 20:5 n-3 (EPA) and 22:6 n-3 (DHA) from 
the capsules are presented in Table 4. The daily intake 
of the long-chain n-3 PUFAs EPA and DHA from the 
Cod-RP capsules was 87 mg/day. Amino acids, taurine, 
EPA and DHA were not detected in the control capsules.
Discussion
Here we show that 8 weeks of cod residual protein sup-
plementation (8.1 g/day) lowered serum concentration of 
NEFA and increased serum TBA concentration compared 
with placebo supplementation, suggesting that cod resid-
uals may have effects beyond being a source of proteins. 
We have previously investigated the effects of cod protein 
supplements on serum markers of lipid metabolism in 
overweight or obese adults (9, 18). To our  knowledge the 
current study is the first to investigate effects of supple-
mentation with cod residual protein on lipid metabolism 
in lean adults.
NEFA is involved in lipid metabolism (22); an elevated 
concentration of NEFA in the circulation is associated 
with obesity and may also be increased in dyslipidemic 
individuals (23). In the present study with lean, physically 
active adults, we observed a significant decrease in serum 
NEFA concentration in the Cod-RP group when com-
pared to the control group. The current findings in NEFA 
is in line with a tendency of lower fasting NEFA concen-
tration in normal-weight adults after consuming 750 g/
week of cod fillet (12) and lower postprandial NEFA con-
centration in overweight or obese adults after cod residual 
protein supplementation (6 g/day) (18).
Reduced serum NEFA concentration and increased 
gene expressions of  the lipogenic enzymes diacylglycer-
ide acyltransferase types 1 and 2 in subcutaneous adi-
pose tissue biopsies have been observed after cod residual 
protein intake in overweight or obese adults (18), thus 
suggesting that lower serum NEFA concentration in 
the current study could be a consequence of  inhibition 
of  NEFA release from adipose tissue. In line with this, 
lower NEFA concentration has also been observed when 
obese Zucker fa/fa rats were fed cod protein as 25% of 
their daily protein intake (14). Thus, a lowering effect 
of  cod proteins on serum NEFA concentration seems to 
Table 3. Estimated daily energy and macronutrient intake
Baseline 8 weeks p† p‡
Mean Standard deviation Mean Standard deviation
Energy intake,1 kcal/day 0.072
 Cod residual protein powder (Cod-RP) group 2,446 681 2,529 665 0.37
 Control group 2,430 486 2,270 469 0.10
Protein1, g/day 0.69
 Cod-RP group 122 39 130 38 0.043
 Control group 112 31 118 31 0.28
Fat, g/day 0.33
 Cod-RP group 100 43 96 36 0.56
 Control group 104 30 92 23 0.089
Carbohydrates, g/day 0.056
 Cod-RP group 238 85 261 79 0.084
 Control group 236 62 219 59 0.28
Note: Results are presented as mean and standard deviation. Estimated daily energy and macronutrient intake are presented for 18 participants in the 
Cod-RP group and 21 participants in the control group.†Within-group differences were compared using a paired-samples t-test.‡Between-group changes 
were compared using the independent samples t-test. The level of significance was set to <0.05.aEnergy and protein intake from the capsules (32 kcal/
day, 8 g/day protein) were included to the end point – dietary record.
Table 4. Daily intake of indispensable amino acids, glycine, taurine, 
and fatty acids from intervention capsulesa
mg/day Cod residual 
protein powder
Control











Eicosapentaenoic acid 39.92 <LOD
Docosahexaenoic acid 47.16 <LOD
aBased on the average of two measurements with deviations <5% 
 between parallels.
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be a consistent finding and may be part of  the benefi-
cial  effects on CVD risk markers associated with lean fish 
consumption (24, 25).
The increased serum TBA in the Cod-RP group may be 
a result of increased conjugation of bile acids with glycine 
and taurine (26, 27). The daily intake of glycine and tau-
rine from the Cod-RP capsules was 683.4 mg and 44.1 mg, 
respectively, and although this contribution of glycine and 
taurine was relatively low we cannot exclude the possibil-
ity that they may have contributed to increase the concen-
tration of conjugated bile acids, thus leading to increased 
serum TBA concentration. The main bile acid species as-
sociated with improved metabolic health are the primary 
and secondary glycine-conjugated bile acids (27). How-
ever, without quantification of individual bile acid species 
we cannot determine which of the specific bile acid species 
contributed to the increased circulating TBA concentra-
tion in the Cod-RP group, and quantification of individual 
bile acid species would be of interest in future studies. The 
increased serum TBA concentration after Cod-RP supple-
mentation could also be a result of more cholesterol being 
used for primary bile acid synthesis (26), as serum LDL 
cholesterol concentration was decreased within the Cod-RP 
group. This is in line with rat studies where intake of protein 
hydrolysates of residual materials from saithe or salmon re-
sulted in higher circulating bile acid concentrations (28, 29), 
but to our knowledge this has not been reported as an effect 
of fish or fish protein intake in humans. The observed in-
crease in serum TBA concentration after Cod-RP supple-
mentation is of interest because a higher circulating TBA 
concentration has been associated with improved metabolic 
health after weight loss following gastric bypass surgery in 
obese adults (27, 30), and drugs that increase bile acid pro-
duction can be used to lower LDL cholesterol (31).
Cross-sectional and follow-up studies have observed 
associations between intake of lean fish and lower serum 
TAG (8, 11) and increased HDL-cholesterol concentra-
tions (8), none of which were observed in the current 
study. Randomized controlled trials with cod protein 
supplements or cod fillet intake have found contrasting 
results. In overweight or obese adults, cod supplements 
reduced the LDL cholesterol concentration (9), which was 
also observed in the current study, albeit only within the 
Cod-RP group. However, in a recent study no changes in 
concentrations of TAG, HDL cholesterol, or LDL choles-
terol were observed after consumption of 750 g/week of 
cod fillet in lean adults (12). This may suggest that a high 
frequency of cod protein intake in the supplement studies 
with three doses per day, as opposed to a lower frequency 
with five cod fillet portions per week, may have more po-
tent effects on lipid metabolism. This is also supported 
by rat studies where lower serum lipid concentrations 
were observed in obese Zucker rats with free access to cod 
protein 24 h/day (14, 16). A frequent cod protein intake 
may have contributed to maintaining a steady state where 
amino acids or other compounds in the cod protein could 
lead to a more constant influence on lipid metabolism.
In addition to a high content of protein, the Cod-RP 
capsules in the current study also contain the long-chain 
n-3 PUFAs EPA and DHA, which could exert beneficial 
health effects (32, 33). However, the contribution of EPA 
and DHA from the Cod-RP capsules was 87 mg/day, 
which is low compared with the general recommended 
intake of >250 mg/day of EPA and DHA based on ob-
served protective effects on cardiovascular heart disease 
mortality, with even higher doses necessary to find effects 
on circulating markers of lipid metabolism (33). Hence, 
EPA and DHA intake from the Cod-RP capsules prob-
ably had insignificant or no effects on the decrease in 
serum NEFA and increase in serum TBA concentrations 
observed in the Cod-RP group.
The current study has some limitations. We did not 
have the necessary information to perform a sample size 
calculation in this pilot study because, to the best of our 
knowledge, no studies have been conducted or published 
on the effects of cod residual protein intake in a group 
of healthy, lean, physically active adults. Hence the sam-
ple size was determined based on experiences from previ-
ous similar clinical studies in overweight or obese adults, 
which may increase the risk of effects not being discov-
ered (type 2 error), if  the sample size was too small.
To conclude, 8 weeks of daily supplementation with 8.1 
g Cod-RP seems to be sufficient to affect lipid metabolism 
in healthy, lean, physically active adults.
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